| Prev Close | 598.54 |
| Day Low/High | 578.43 / 600.14 |
| 52 Wk Low/High | 271.37 / 618.71 |
| Avg Volume | 1.56M |
Regeneron Pharmaceuticals Inc. (REGN)
597.00
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 110.67M |
| Market Cap | 67.99B |
| EPS | 19.40 |
| P/E Ratio | 30.08 |
| Div & Yield | N.A. (N.A) |
Ophthtech Shares Plunge as Drug Fails in Late Stage Trial
A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.
Cramer: With Trump, Everything's a Negotiation
Just ask the drug companies or Boeing.
Cramer: We Are in Stage 2 of the Trump Love Affair With Business
Hillary isn't the only one who seems to favor workers over capital. Trump does, too.
Takeover Talk Surrounds Biotech Firm Alexion, Says Jim Cramer
Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.
Markets Await October Jobs Report Friday
The October jobs report is released on Friday, November 4th at 8:30 a.m. Eastern.
Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case
It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.
FDA Puts Hold on Regeneron Pain-Drug Study
Shares of Regeneron Pharmaceuticals were lower Monday after The Food and Drug Administration put a drug study on hold.
Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide
On days like this, the money just keeps sloshing around.
Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
Cramer: Here's What to Embrace and What to Shun
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
Amgen and Regeneron Expanding Anti-Cancer Research
The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.
Cramer: What Are You Thinking? It Should Be Long Term
That may be the best way to get through the notorious month of August.
Jim Cramer: I’m Looking at the Biotechs
Utilities and other high yielding sectors are reaching overbought levels, so investors may want to rotate into biotechs, says Jim Cramer.
Regeneron Is Regenerating Lost Profits
Investors should risk below $380 for now.
Cramer: Might Something Be Brewing in 3 Downtrodden Sectors?
Biotech, restaurants and retail have been left for dead but are showing signs of life today.
Regeneron Tries to Recover From Lows
Prices pop today, but is this a reversal?
Regeneron May Cure the Market Blues
A potentially bullish pattern is setting up.
How to Trade Regeneron's Pullback
Aggressive traders can go long REGN on the first up day.
Cramer: Here's Why Facebook's Stock Has Been Falling
Stocks like Facebook or Palo Alto Networks are expensive for the moment.
Cramer: See What Happens When Takeover Talk Gets Going?
With Pfizer deal dead, Allergan is ready to go shopping.
Regeneron's Chart Has Degenerative Look
The biopharmaceutical company's chart is still pointed lower.
Jim Cramer Says Oracle Is Okay, But He Really Likes Salesforce.com
TheStreet’s Jim Cramer discussed the bear market in biotechs while answering viewer questions from social media on Friday.
Midday Report: Fox News Hits Record Profit; U.S. Stocks Waver
U.S. stocks gave up earlier gains as the energy sector continued to sell off despite relatively stable crude prices on Tuesday.
Double Top Could Spell Double Trouble for Regeneron
The biopharmaceutical company is in for a deeper bear phase.
Cramer: This Is Where I Say I Was Wrong
My speculation on Fitbit and Alcoa didn't work out.
Jim Cramer Says Own Salesforce.com, Regeneron, First Solar
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.
Have a CIGAR, You'll Go Far in 2016
5 biotech stocks that could outperform the overall market in 2016.
Jim Cramer on Why Netflix, Chipotle and Regeneron Soared During QE
TheStreet looked at stocks that soared under the Federal Reserve’s QE program, and Jim Cramer explains why some shares performed better than others.
